TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions
Oct 6, 2022
For people with early Alzheimer's (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals For people with mild to moderate Alzheimer's, HMTM stabilised cognition and function and reduced rate of brain atrophy compared to historical matched individuals with AD HMTM is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities TauRx